If you follow Verastem (NASDAQ:VSTM), you probably know that they've had a very good 2017, going from $1.14 to open the year up to $5.40 as of me writing this. An article by Jonathan Faison called Verastem Outlook Post Duo Results does an excellent job explaining VSTM's phase 3 trial data for Duvelisib (DUO for short), so I won't rehash that. What I've been thinking about recently is trying to get some sort of valuation for VSTM. Since it is already up over 400% from its 52-week lows, I'm sure many investors are wondering, "Is there room left to run or is it more risk than reward at this point?"
In this article I set out to provide some analysis of the expected revenues for DUO and ultimately a valuation for them. I've been trying to learn as much as I can about the BioTech and pharmaceutical industries, but I am by no means an expert. I will go over a best case possibility, a couple other more likely scenarios, and the worst case possibility.